Endpoint Consulting
Strategic endpoint selection and development for global CNS clinical trials. The measurement decisions made in early development define the sensitivity and regulatory acceptance of every subsequent trial. We work across FDA, EMA, and Health Canada.
Endpoint strategy is the invisible architecture of a clinical program. The endpoints chosen in Phase 1 and Phase 2 determine whether Phase 3 will have the sensitivity to detect real treatment effects. They determine whether regulatory reviewers will accept the evidence of efficacy per FDA PFDD guidance on incorporating clinical outcome assessments into endpoints. And they determine whether the investment of years and hundreds of millions of dollars will produce an approvable product.
We specialize in the CNS therapeutic space where endpoint selection is particularly challenging. Neurological and psychiatric conditions present with heterogeneous symptom profiles, subjective assessment tools with limited sensitivity, and a regulatory landscape that is actively evolving as digital endpoints gain acceptance across global regulatory bodies.
Our approach starts with the clinical question your therapeutic is designed to answer, works backward through the regulatory requirements for your target indication and target markets, and arrives at a measurement strategy that is scientifically valid and regulatorily defensible. We align with FDA guidance on incorporating clinical outcome assessments into endpoints for regulatory decision-making, and integrate traditional COAs with digital endpoints like NeuroQuantix to provide the multidimensional sensitivity that modern CNS trials demand.
We engage at the earliest stages of development because the cost of correcting an endpoint strategy mid-program is measured in years and tens of millions of dollars. For gene therapy programs with small, rare-disease populations, this is the difference between a successful submission and a clinical hold.
Frequently Asked Questions
What is clinical outcome assessment (COA) consulting?
COA consulting helps sponsors select, validate, and defend the clinical outcome assessments used as endpoints in clinical trials. This includes evaluating existing rating scales, integrating digital endpoints, navigating COA/DDT qualification pathways, and building endpoint strategies aligned with FDA, EMA, and Health Canada requirements.
How does endpoint strategy differ between Phase 1 and Phase 3?
Phase 1 endpoint strategy focuses on establishing the measurement foundation: selecting sensitive assessments, validating digital endpoints, and aligning with regulatory expectations. Phase 3 requires regulatory-grade endpoints with demonstrated reliability, validity, and responsiveness.
What is the COA/DDT qualification pathway for digital endpoints?
The Clinical Outcome Assessment / Drug Development Tool qualification pathway allows sponsors to qualify a measurement tool for use across multiple drug development programs. For digital endpoints like NeuroQuantix, this involves demonstrating reliability, validity, responsiveness, and clinical meaningfulness.
When should sponsors consider digital endpoints alongside traditional rating scales?
Sponsors should consider digital endpoints when traditional scales show limited sensitivity, high inter-rater variability, or insufficient resolution to detect treatment effects at planned sample sizes. Digital endpoints are particularly valuable for rare disease and gene therapy programs.
What We Deliver
Endpoint Selection Strategy
Identification and evaluation of primary, secondary, and exploratory endpoints aligned with your therapeutic mechanism, target population, and regulatory pathway across global markets.
Assessment Tool Evaluation
Critical analysis of existing rating scales, digital biomarkers, and performance-based measures. Head-to-head comparison of sensitivity, reliability, and regulatory precedent for your target indication.
Digital Endpoint Integration
Strategy for incorporating digital and technology-based endpoints alongside traditional COAs. NeuroQuantix and other digital biomarker platforms integrated into your endpoint portfolio.
Global Regulatory Alignment
Ensure endpoint strategy aligns with FDA, EMA, and Health Canada guidance. Navigate jurisdiction-specific requirements and build strategies that support multi-regional submissions.
Statistical Sensitivity Analysis
Power analysis and effect size modeling to ensure selected endpoints can detect clinically meaningful treatment effects at planned sample sizes. Optimize your trial design for endpoint sensitivity.
Longitudinal Endpoint Design
Design measurement strategies that capture treatment effects across the full trial duration, including responder analyses, time-to-event frameworks, and composite endpoint construction.
Typical Deliverables
Related Resources
NeuroQuantix Platform
Regulatory-grade digital endpoints from published spiral analysis methodology. The technology behind our consulting.
Central Rater Committees
Complement your endpoint strategy with consistent, calibrated rater infrastructure.
21 CFR Part 11 Compliance
CDISC data standards, audit trails, and regulatory-grade infrastructure supporting your endpoints.
Published Research
Evidence base from our scoping review in Movement Disorders Clinical Practice.
Get your endpoint strategy right from the start
From preclinical planning through mid-program course correction, we build endpoint strategies that stand up to regulatory scrutiny in any market worldwide.
Start the Conversation